If healthy cells use a mitochondrial respiratory chain, tumors use aerobic glycolysis, a routine that allows them holding appetite fast though depending on glucose. This materialisation -known as a Warburg effect- is caused by several changes that take place during dungeon transformation.
Now, a new essay describes an epigenetic damage found in tellurian tumours that combined this altered trail to take appetite from a cancer. The study, published in Journal of Clinical Investigation Insight, is a new investigate carried out by a organisation led by Manel Esteller, highbrow of Genetics of a Faculty of Medicine and Health Sciences of a University of Barcelona (UB), ICREA researcher, coordinator of a Cancer Epigenetics and Biology Program during IDIBELL, and executive of a Josep Carreras Institute.
According to Professor Esteller, who led a new systematic study, “we found squamous tumors -in a head, neck, esophagus and cervix- uncover activity detriment of a SVIP gen, that prevents decrease of proteins that are critical for dungeon balance. The error in a SVIP gene duty causes a drop of a metabolic mechanisms that concede glucose’s physiologic use to get appetite in a tranquil way, and that is finally transposed by a kind of molecular “fast food” that gets inexpensive appetite for a expansion cell.”
“We have also seen patients with this metabolic change that uncover a shorter presence over a march of their disease,” continues Manel Esteller. “However, cancer cells’ obsession to glucose could be their weakness. Therefore, pre-clinical studies uncover that patients with a epigenetic detriment of a SVIP gene are supportive to drugs opposite glucose receptor, that retard a opening of this proton and means a kind of ‘abstinence syndrome’ of a expansion that binds their expansion back.”
Participants in a new study, with a categorical authors being Pere Llinàs Arias and Margalida Rosselló Tortella (IDIBELL), are a experts Marta Cascante and Sílvia Marín, from a Faculty of Biology of a UB, a Institute of Biomedicine of a UB (IBUB) and a Liver and Digestive Diseases Networking Biomedical Research Centre (CIBEREHD); Antonio Zorzano, from a Faculty of Biology of a UB, a Institute for Research in Biomedicine (IRB Barcelona), and a Diabetes and Associated Metabolic Diseases Networking Biomedical Research Centre (CIBERDEM), and Juan P. Muñoz (Faculty of Biology of a UB, IRB Barcelona and CIBERDEM, among others).